AI for Bio · Model

Origin-1

Generative platform designing full-length antibodies de novo against zero-prior epitopes, combining diffusion generation, paired CDR sequence design and co-folding scoring

AntibodiesAI-native biotechUnited StatesActive中文

Overview

NameOrigin-1 · aliases: Origin-1, AbsciGen, AbsciBind
Full nameThe name is a platform name; the preprint gives no expanded form
Ambiguous names (not auto-linked)Origin
FamilyNot a family entry. A single platform whose components are described inside one record
OrganizationAbsci
Organization typeAI-native biotech
CountryUnited States
Model classDesign (all-atom diffusion, sequence design, scoring)
DomainAntibodies (also: Structure & co-folding)
First release · preprint
Basis: Preprint v1 posted, with a developer launch page the same day
Note: Materials giving 2026-03 refer to a results-disclosure date, not first release source
Other milestones
  • First public evidence: · Preprint v1 source
  • Preprint v1: · Preprint v1 source
  • Code release: † · Data and evaluation scripts in a public repository; weights not included source
  • Official announcement: · Developer launch page source
Latest update · paper revision
Basis: Preprint v2
The preprint was revised to v2; afterwards the public repository saw only maintenance edits to data tables and the readme (latest 2026-11-13), and no journal version was found source
The most recent sourced event, not a claim that nothing changed since.
StatusActive · Preprint revision and repository maintenance within 12 months
OpennessCode: Partly open
Weights: Unclear
Data and evaluation are in a public repository; neither the paper nor the website states whether weights are released or under what terms
Benchmarks reported0 counted · none of the 44
Wet-lab validation2 recorded campaigns
Unverified fields† open_status.weights, training_data.c_own_wetlab_for_training, wetlab_validation[1]
As of2026-11-16

What it does

Conditions on an unbound antigen structure, an antibody framework and a user-specified epitope to generate the complex by all-atom diffusion, designs paired heavy and light chain sequences for six CDRs, then screens with co-folding scoring before the wet lab. Against RFantibody it is all-atom, allows antigen flexibility and explicitly targets zero-prior epitopes; against BoltzGen its antibody evidence lies in full-length antibodies rather than nanobodies.

Benchmarks reported

None of the 44 benchmarks. This model is on the zero-pairing list.

How it evaluates itself: In silico comparison vs RFantibody; AbsciBind discrimination; Zero-prior epitope design, 10 targets; IL36RA affinity maturation

Other evaluations (outside the 44)

  • In-silico comparison with an open antibody design model (Comparison against baselines only) Self-reported: Compares the share of designs passing the developer's own score on four zero-prior targets; not an experimental hit-rate comparison
  • Own assessment of the scoring module (Own task set) Self-reported: Separates binders from non-binders across eight antibody-antigen systems against several co-folding models, with some comparator values taken from other papers

Developers report: Developers report de novo full-length antibodies against targets with no known complex structure, with four of ten targets yielding developable binders from fewer than 100 designs each.

Independent evidence: No independent evidence found. No third-party assessment or replication was found; earlier critiques of this developer concern a separate 2023 piece of work, not this model

Training data

Group in Figure 7: Public data + wet lab for validation only.

ClassValueDetail
a. Public databasesYesAn in-house antibody structure set from 10,045 public structure-database entries, covering all entries of a dedicated antibody database, with homologous complexes of the zero-prior targets excluded from every split source
b. Private or licensed dataNo source
c. Own wet-lab data used for trainingNot disclosedThe methods section describes only public structure data, while the website also mentions years of proprietary data generation and closed-loop experiments without scale or composition source
d. Wet lab used only for validationYesBinding, specificity, aggregation, structural and functional assays across ten targets source

Wet-lab validation

Every rate carries its numerator and denominator. Claims that could not be verified are shown as unverified, without numbers; different paper versions are separate entries.

Zero-prior epitope design (ten targets) (preprint v1 / developer page)
Targets 10 · Designs tested — · Hits 4 · Success 4/10 targets · Best affinity —

Denominator basis: Ten targets with fewer than 100 designs each; hits counted per target as developable antibodies passing several orthogonal assays
Two of the targets also have cryo-EM structures matching the designs at 3.0 A and 3.1 A; the developers note few hits per target, few designs and stricter acceptance criteria
Executor: Run by the developer; no independent experimental arm

Self-reported · · verified · source
Affinity maturation on one target (developer page)
Targets 1† · Designs tested — · Hits — · Success — · Best affinity —

Denominator basis: An AI-guided single-mutation library whose size and number tested are not given on the launch page
The developers report a functional antagonist after maturation with a tens-fold affinity gain; self-reported
Executor: Run by the developer

Self-reported · † · †partly verified · source

Background

  • Organization: The developer is a US-listed AI-native drug discovery company headquartered in Washington state with sites in New York, Switzerland and Serbia, and 140 employees at end-2025 per its annual report.
  • Funding: A listed company; in 2025-01 a semiconductor company subscribed $20M of its shares per the annual report.
  • Products and partnerships: The annual report lists collaborations with several research institutions and companies; the clinical pipeline centres on one antibody candidate and no trial application tied to this model is disclosed.
  • Related models: RFantibody, BoltzGen, Chai-1

Reading notes

  1. It is relatively strong public evidence for zero-prior epitopes with full-length antibodies and structural confirmation, but hits per target and design counts are small.
  2. The gap against the open model uses the developer's own score on only four targets and is not an experimental hit rate.
  3. No antibody benchmark on this site lists it, so generalisation can only be judged by third parties reproducing it on zero-prior targets.
  4. Whether weights are public is unstated, which limits external reproduction.

Caveats

  1. All results are self-reported, with no peer-reviewed version and no independent experimental arm.
  2. The exact affinity-maturation value is absent from the launch page and must be sourced from the paper before citation.
  3. The proprietary data and closed-loop experiments mentioned on the website come without scale, so training data composition cannot be judged from them.
  4. Under this round's relation rules it has no countable pairing with any benchmark on this site.

Sources

  1. Preprint (developer PDF) (preprint) · 2026-01-14
  2. Preprint version record (registry)
  3. Developer launch page (official page)
  4. Data and evaluation repository (repository)

Corrections

2 corrections
FieldWasNowBasisFound
wetlab_validationAffinity maturation gives exact potency valuesThe release page gives only approximate values; exact values must be taken from the paper, so none are shown for nowsource2026-11-16
training_data.c_own_wetlab_for_trainingOwn experimental data used in trainingThe paper's methods section mentions only public structure data and the website claim has no scale, so it is treated as not disclosedsource2026-11-16

Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-16.